recombinant human sfrp1 protein cf Search Results


human sfrp 1 protein  (R&D Systems)
94
R&D Systems human sfrp 1 protein
Human Sfrp 1 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+sfrp1+protein+cf/pmc05550904-253-18-23?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
human sfrp 1 protein - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
human sfrp 1  (R&D Systems)
93
R&D Systems human sfrp 1
Human Sfrp 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+sfrp1+protein+cf/pm23028669-183-13-17?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
human sfrp 1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
human recombinant wnt1 protein  (R&D Systems)
90
R&D Systems human recombinant wnt1 protein
<t>(A)Recombinant</t> human <t>Wnt1</t> protein (100 ng/ml) was applied to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and cell survival was determined 48 hours later. Representative images illustrate increased trypan blue staining during elevated glucose, but administration of Wnt1 significantly decreased trypan blue uptake by ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein antagonized the ability of Wnt1 to significantly reduce trypan blue uptake in ECs during elevated glucose exposure. (B) Wnt1 (100 ng/ml) administration significantly increased EC survival when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein blocked Wnt1 cytoprotection in ECs during elevated glucose (†p<0.01 vs. Wnt1/HG). (C) Recombinant human Wnt1 protein (100 ng/ml) was administered to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and nuclear DNA fragmentation with TUNEL was determined 48 hours later. Representative images illustrate increased TUNEL staining during elevated glucose, but administration of Wnt1 significantly decreased TUNEL labeling in ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein antagonized the ability of Wnt1 to significantly reduce TUNEL labeling in ECs during elevated glucose exposure. (D) Wnt1 (100 ng/ml) administration significantly decreased EC nuclear DNA degradation when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein prevented Wnt1 from reducing nuclear DNA degradation in ECs during elevated glucose (†p<0.01 vs. Wnt1/HG). In all cases, each data point represents the mean and SEM and control = untreated EC cultures.
Human Recombinant Wnt1 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+sfrp1+protein+cf/pmc02678063-68-18-22?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
human recombinant wnt1 protein - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
recombinant human sfrp-1 (histidine-tagged) protein, cf  (Bio-Techne corporation)
92
Bio-Techne corporation recombinant human sfrp-1 (histidine-tagged) protein, cf
<t>(A)Recombinant</t> human <t>Wnt1</t> protein (100 ng/ml) was applied to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and cell survival was determined 48 hours later. Representative images illustrate increased trypan blue staining during elevated glucose, but administration of Wnt1 significantly decreased trypan blue uptake by ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein antagonized the ability of Wnt1 to significantly reduce trypan blue uptake in ECs during elevated glucose exposure. (B) Wnt1 (100 ng/ml) administration significantly increased EC survival when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein blocked Wnt1 cytoprotection in ECs during elevated glucose (†p<0.01 vs. Wnt1/HG). (C) Recombinant human Wnt1 protein (100 ng/ml) was administered to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and nuclear DNA fragmentation with TUNEL was determined 48 hours later. Representative images illustrate increased TUNEL staining during elevated glucose, but administration of Wnt1 significantly decreased TUNEL labeling in ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein antagonized the ability of Wnt1 to significantly reduce TUNEL labeling in ECs during elevated glucose exposure. (D) Wnt1 (100 ng/ml) administration significantly decreased EC nuclear DNA degradation when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein prevented Wnt1 from reducing nuclear DNA degradation in ECs during elevated glucose (†p<0.01 vs. Wnt1/HG). In all cases, each data point represents the mean and SEM and control = untreated EC cultures.
Recombinant Human Sfrp 1 (Histidine Tagged) Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+sfrp1+protein+cf/bio-techne+corporation___1384-sf-cf?v=Bio-Techne+corporation
Average 92 stars, based on 1 article reviews
recombinant human sfrp-1 (histidine-tagged) protein, cf - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
recombinant human sfrp 1 histidine tagged protein cf  (R&D Systems)
N/A
The Recombinant Human sFRP 1 Histidine tagged Protein from R D Systems is derived from NS0 The Recombinant Human sFRP 1 Histidine tagged Protein has been validated for the following applications Bioactivity
   Buy from Supplier
recombinant human sfrp 1 protein cf  (R&D Systems)
N/A
The Recombinant Human sFRP 1 Protein from R D Systems is derived from NS0 The Recombinant Human sFRP 1 Protein has been validated for the following applications Bioactivity
   Buy from Supplier
recombinant human sfrp-1 (histidine-tagged) protein, cf  (R&D Systems)
N/A
Recombinant Human sFRP-1 (Histidine-tagged) Protein, CF
   Buy from Supplier
recombinant human wnt-2/sfrp-1 complex protein, cf  (R&D Systems)
N/A
Recombinant Human Wnt-2/sFRP-1 Complex Protein, CF
   Buy from Supplier

Image Search Results


(A)Recombinant human Wnt1 protein (100 ng/ml) was applied to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and cell survival was determined 48 hours later. Representative images illustrate increased trypan blue staining during elevated glucose, but administration of Wnt1 significantly decreased trypan blue uptake by ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein antagonized the ability of Wnt1 to significantly reduce trypan blue uptake in ECs during elevated glucose exposure. (B) Wnt1 (100 ng/ml) administration significantly increased EC survival when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein blocked Wnt1 cytoprotection in ECs during elevated glucose (†p<0.01 vs. Wnt1/HG). (C) Recombinant human Wnt1 protein (100 ng/ml) was administered to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and nuclear DNA fragmentation with TUNEL was determined 48 hours later. Representative images illustrate increased TUNEL staining during elevated glucose, but administration of Wnt1 significantly decreased TUNEL labeling in ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein antagonized the ability of Wnt1 to significantly reduce TUNEL labeling in ECs during elevated glucose exposure. (D) Wnt1 (100 ng/ml) administration significantly decreased EC nuclear DNA degradation when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein prevented Wnt1 from reducing nuclear DNA degradation in ECs during elevated glucose (†p<0.01 vs. Wnt1/HG). In all cases, each data point represents the mean and SEM and control = untreated EC cultures.

Journal:

Article Title: VASCULAR INJURY DURING ELEVATED GLUCOSE CAN BE MITIGATED BY ERYTHROPOIETIN AND WNT SIGNALING

doi:

Figure Lengend Snippet: (A)Recombinant human Wnt1 protein (100 ng/ml) was applied to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and cell survival was determined 48 hours later. Representative images illustrate increased trypan blue staining during elevated glucose, but administration of Wnt1 significantly decreased trypan blue uptake by ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein antagonized the ability of Wnt1 to significantly reduce trypan blue uptake in ECs during elevated glucose exposure. (B) Wnt1 (100 ng/ml) administration significantly increased EC survival when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein blocked Wnt1 cytoprotection in ECs during elevated glucose (†p<0.01 vs. Wnt1/HG). (C) Recombinant human Wnt1 protein (100 ng/ml) was administered to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and nuclear DNA fragmentation with TUNEL was determined 48 hours later. Representative images illustrate increased TUNEL staining during elevated glucose, but administration of Wnt1 significantly decreased TUNEL labeling in ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein antagonized the ability of Wnt1 to significantly reduce TUNEL labeling in ECs during elevated glucose exposure. (D) Wnt1 (100 ng/ml) administration significantly decreased EC nuclear DNA degradation when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of Wnt1 protein prevented Wnt1 from reducing nuclear DNA degradation in ECs during elevated glucose (†p<0.01 vs. Wnt1/HG). In all cases, each data point represents the mean and SEM and control = untreated EC cultures.

Article Snippet: For treatments applied 1 hour prior to elevated glucose concentrations, application of erythropoietin (EPO) (R&D Systems, Minneapolis, MN), human recombinant Wnt1 protein (R&D Systems, Minneapolis, MN), a mouse monoclonal anti body against Wnt1 (R&D Systems, 0olis, MN), or the glycogen synthase kinase (GSK)-3β inhibitor SB216763 [3-(2,4-Dichlorophenyl)-4-(1-methyl- 1 H-indol-3-yl)- 1 H-pyrrole-2,5-dione] (SB21) (Tocris, Ellisville, MO) were continuous.

Techniques: Recombinant, Staining, TUNEL Assay, Labeling, Control

(A)EPO (10 ng/ml) was applied to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and cell survival was determined 48 hours later. Representative images illustrate increased trypan blue staining during elevated glucose, but administration of EPO significantly decreased trypan blue uptake by ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of EPO antagonized the ability of EPO to prevent trypan blue uptake in ECs during elevated glucose exposure. (B) EPO (10 ng/ml) application significantly increased EC survival when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the EPO treatment blocked Wnt1 cytoprotection in ECs during elevated glucose (†p<0.01 vs. EPO/HG). (C) EPO (10 ng/ml) was applied to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and nuclear DNA fragmentation with TUNEL was determined 48 hours later. Representative images illustrate increased TUNEL staining during elevated glucose, but administration of EPO significantly decreased nuclear DNA fragmentation as demonstrated by reduced TUNEL labeling in ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of EPO prevented EPO from significantly reducing TUNEL labeling in ECs during elevated glucose exposure. (D) EPO (10 ng/ml) administration significantly decreased EC nuclear DNA degradation when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to EPO application prevented EPO from reducing nuclear DNA degradation in ECs during elevated glucose (†p<0.01 vs. EPO/HG). In all cases, each data point represents the mean and SEM and control = untreated EC cultures.

Journal:

Article Title: VASCULAR INJURY DURING ELEVATED GLUCOSE CAN BE MITIGATED BY ERYTHROPOIETIN AND WNT SIGNALING

doi:

Figure Lengend Snippet: (A)EPO (10 ng/ml) was applied to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and cell survival was determined 48 hours later. Representative images illustrate increased trypan blue staining during elevated glucose, but administration of EPO significantly decreased trypan blue uptake by ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of EPO antagonized the ability of EPO to prevent trypan blue uptake in ECs during elevated glucose exposure. (B) EPO (10 ng/ml) application significantly increased EC survival when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the EPO treatment blocked Wnt1 cytoprotection in ECs during elevated glucose (†p<0.01 vs. EPO/HG). (C) EPO (10 ng/ml) was applied to EC cultures 1 hour prior to the exposure of D-glucose (25 mM) (HG) and nuclear DNA fragmentation with TUNEL was determined 48 hours later. Representative images illustrate increased TUNEL staining during elevated glucose, but administration of EPO significantly decreased nuclear DNA fragmentation as demonstrated by reduced TUNEL labeling in ECs. In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to the administration of EPO prevented EPO from significantly reducing TUNEL labeling in ECs during elevated glucose exposure. (D) EPO (10 ng/ml) administration significantly decreased EC nuclear DNA degradation when compared with cultures exposed to elevated glucose alone (*p<0.01 vs. HG). In contrast, application of Wnt1 antibody (Wnt1Ab, 1 μg/ml) 30 min prior to EPO application prevented EPO from reducing nuclear DNA degradation in ECs during elevated glucose (†p<0.01 vs. EPO/HG). In all cases, each data point represents the mean and SEM and control = untreated EC cultures.

Article Snippet: For treatments applied 1 hour prior to elevated glucose concentrations, application of erythropoietin (EPO) (R&D Systems, Minneapolis, MN), human recombinant Wnt1 protein (R&D Systems, Minneapolis, MN), a mouse monoclonal anti body against Wnt1 (R&D Systems, 0olis, MN), or the glycogen synthase kinase (GSK)-3β inhibitor SB216763 [3-(2,4-Dichlorophenyl)-4-(1-methyl- 1 H-indol-3-yl)- 1 H-pyrrole-2,5-dione] (SB21) (Tocris, Ellisville, MO) were continuous.

Techniques: Staining, TUNEL Assay, Labeling, Control

EC protein extracts (50 μg/lane) were immunoblotted with anti-Wnt1 (A and B), anti-phosphorylated glycogen synthase kinase-3β (anti-p-GSK-3β) (C and D). Representative images of Western blot detection for Wnt1 (A) and p-GSK-3β (C) were performed at 6, 24, and 48 hour time intervals following administration of elevated D-glucose (25 mM) (HG). Wnt1 and p-GSK-3β expression increased at 6 and 24 hours following exposure to high glucose, but expression of these proteins was lost 48 hours following elevated glucose (*p< 0.01 vs. 6 hours or 24 hours HG). Application of EPO (10 ng/ml) 1 hour prior to the administration of elevated glucose significantly increased Wnt1 (B) (*p< 0.01 vs. HG) and p-GSK-3β (D) (*p< 0.01 vs. HG) expression 48 hours following elevated glucose treatment. In all cases, each data point represents the mean and SEM and control = untreated EC cultures.

Journal:

Article Title: VASCULAR INJURY DURING ELEVATED GLUCOSE CAN BE MITIGATED BY ERYTHROPOIETIN AND WNT SIGNALING

doi:

Figure Lengend Snippet: EC protein extracts (50 μg/lane) were immunoblotted with anti-Wnt1 (A and B), anti-phosphorylated glycogen synthase kinase-3β (anti-p-GSK-3β) (C and D). Representative images of Western blot detection for Wnt1 (A) and p-GSK-3β (C) were performed at 6, 24, and 48 hour time intervals following administration of elevated D-glucose (25 mM) (HG). Wnt1 and p-GSK-3β expression increased at 6 and 24 hours following exposure to high glucose, but expression of these proteins was lost 48 hours following elevated glucose (*p< 0.01 vs. 6 hours or 24 hours HG). Application of EPO (10 ng/ml) 1 hour prior to the administration of elevated glucose significantly increased Wnt1 (B) (*p< 0.01 vs. HG) and p-GSK-3β (D) (*p< 0.01 vs. HG) expression 48 hours following elevated glucose treatment. In all cases, each data point represents the mean and SEM and control = untreated EC cultures.

Article Snippet: For treatments applied 1 hour prior to elevated glucose concentrations, application of erythropoietin (EPO) (R&D Systems, Minneapolis, MN), human recombinant Wnt1 protein (R&D Systems, Minneapolis, MN), a mouse monoclonal anti body against Wnt1 (R&D Systems, 0olis, MN), or the glycogen synthase kinase (GSK)-3β inhibitor SB216763 [3-(2,4-Dichlorophenyl)-4-(1-methyl- 1 H-indol-3-yl)- 1 H-pyrrole-2,5-dione] (SB21) (Tocris, Ellisville, MO) were continuous.

Techniques: Western Blot, Expressing, Control

Primary ECs were exposed to elevated D-glucose (25 mM) (HG) and EC survival or nuclear DNA fragmentation were determined 48 hours following elevated glucose exposure. (A and C) Elevated glucose resulted in a significant decrease EC survival and a significant increase in nuclear DNA fragmentation in ECs. Application of the GSK-3β inhibitor SB21 (5 μM) 1 hour prior to administration of elevated D-glucose significantly increased cell survival and decreased nuclear DNA fragmentation 48 hours following elevated glucose treatment (*p<0.01 vs. HG). Co-application of Wnt1 antibody (Wnt1Ab) did not alter the ability of SB21 to protect ECs during elevated glucose treatment (*P<0.01 vs. HG). (B and D) EPO (10 ng/ml) administered 1 hour prior to elevated D-glucose (25 mM) application significantly increased cell survival and decreased nuclear DNA fragmentation in ECs 48 hours following elevated glucose treatment (*p<0.01 vs. HG). Co-application of GSK-3β inhibitor SB21 with EPO significantly increased survival and decreased apoptotic nuclear DNA degradation during elevated glucose exposure, but lead to similar survival levels and DNA degradation during EPO administration alone with elevated glucose without a synergistic increase, suggesting that EPO requires the inhibition of GSK-3β activity for cytoprotection in ECs (*p<0.01 vs. HG alone). In all cases, each data point represents the mean and SEM and control = untreated EC cultures.

Journal:

Article Title: VASCULAR INJURY DURING ELEVATED GLUCOSE CAN BE MITIGATED BY ERYTHROPOIETIN AND WNT SIGNALING

doi:

Figure Lengend Snippet: Primary ECs were exposed to elevated D-glucose (25 mM) (HG) and EC survival or nuclear DNA fragmentation were determined 48 hours following elevated glucose exposure. (A and C) Elevated glucose resulted in a significant decrease EC survival and a significant increase in nuclear DNA fragmentation in ECs. Application of the GSK-3β inhibitor SB21 (5 μM) 1 hour prior to administration of elevated D-glucose significantly increased cell survival and decreased nuclear DNA fragmentation 48 hours following elevated glucose treatment (*p<0.01 vs. HG). Co-application of Wnt1 antibody (Wnt1Ab) did not alter the ability of SB21 to protect ECs during elevated glucose treatment (*P<0.01 vs. HG). (B and D) EPO (10 ng/ml) administered 1 hour prior to elevated D-glucose (25 mM) application significantly increased cell survival and decreased nuclear DNA fragmentation in ECs 48 hours following elevated glucose treatment (*p<0.01 vs. HG). Co-application of GSK-3β inhibitor SB21 with EPO significantly increased survival and decreased apoptotic nuclear DNA degradation during elevated glucose exposure, but lead to similar survival levels and DNA degradation during EPO administration alone with elevated glucose without a synergistic increase, suggesting that EPO requires the inhibition of GSK-3β activity for cytoprotection in ECs (*p<0.01 vs. HG alone). In all cases, each data point represents the mean and SEM and control = untreated EC cultures.

Article Snippet: For treatments applied 1 hour prior to elevated glucose concentrations, application of erythropoietin (EPO) (R&D Systems, Minneapolis, MN), human recombinant Wnt1 protein (R&D Systems, Minneapolis, MN), a mouse monoclonal anti body against Wnt1 (R&D Systems, 0olis, MN), or the glycogen synthase kinase (GSK)-3β inhibitor SB216763 [3-(2,4-Dichlorophenyl)-4-(1-methyl- 1 H-indol-3-yl)- 1 H-pyrrole-2,5-dione] (SB21) (Tocris, Ellisville, MO) were continuous.

Techniques: Inhibition, Activity Assay, Control